Literature DB >> 19351908

Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport.

Florence T H Wu1, Marianne O Stefanini, Feilim Mac Gabhann, Christopher D Kontos, Brian H Annex, Aleksander S Popel.   

Abstract

Vascular endothelial growth factor (VEGF) signal transduction through the cell surface receptors VEGFR1 and VEGFR2 regulates angiogenesis-the growth of new capillaries from preexistent microvasculature. Soluble VEGF receptor-1 (sVEGFR1), a nonsignaling truncated variant of VEGFR1, has been postulated to inhibit angiogenic signaling via direct sequestration of VEGF ligands or dominant-negative heterodimerization with surface VEGFRs. The relative contributions of these two mechanisms to sVEGFR1's purported antiangiogenic effects in vivo are currently unknown. We previously developed a computational model for predicting the compartmental distributions of VEGF and sVEGFR1 throughout the healthy human body by simulating the molecular interaction networks of the VEGF ligand-receptor system as well as intercompartmental macromolecular biotransport processes. In this study, we decipher the dynamic processes that led to our prior prediction that sVEGFR1, through its ligand trapping mechanism alone, does not demonstrate significant steady-state antiangiogenic effects. We show that sVEGFR1-facilitated tissue-to-blood shuttling of VEGF accounts for a counterintuitive and drastic elevation in plasma free VEGF concentrations after both intramuscular and intravascular sVEGFR1 infusion. While increasing intramuscular VEGF production reduces free sVEGFR1 levels through increased VEGF-sVEGFR1 complex formation, we demonstrate a competing and opposite effect in which increased VEGF occupancy of neuropilin-1 (NRP1) and the corresponding reduction in NRP1 availability for internalization of sVEGFR1 unexpectedly increases free sVEGFR1 levels. In conclusion, dynamic intercompartmental transport processes give rise to our surprising prediction that VEGF trapping alone does not account for sVEGFR1's antiangiogenic potential. sVEGFR1's interactions with cell surface receptors such as NRP1 are also expected to affect its molecular interplay with VEGF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351908      PMCID: PMC2696151          DOI: 10.1152/physiolgenomics.00031.2009

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  42 in total

1.  Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered?

Authors:  Aernout Luttun; Peter Carmeliet
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 2.  Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question.

Authors:  S Ananth Karumanchi; Yuval Bdolah
Journal:  Endocrinology       Date:  2004-11       Impact factor: 4.736

3.  Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.

Authors:  Katrin Lamszus; Ulrike Ulbricht; Jakob Matschke; Marc A Brockmann; Regina Fillbrandt; Manfred Westphal
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

4.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.

Authors:  R L Kendall; K A Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

5.  Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis.

Authors:  J Miotla; R Maciewicz; J Kendrew; M Feldmann; E Paleolog
Journal:  Lab Invest       Date:  2000-08       Impact factor: 5.662

6.  Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids.

Authors:  C Hornig; B Barleon; S Ahmad; P Vuorela; A Ahmed; H A Weich
Journal:  Lab Invest       Date:  2000-04       Impact factor: 5.662

7.  Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways.

Authors:  Susana Constantino Rosa Santos; Sérgio Dias
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

8.  Differential expression of VEGF isoforms in mouse during development and in the adult.

Authors:  Y S Ng; R Rohan; M E Sunday; D E Demello; P A D'Amore
Journal:  Dev Dyn       Date:  2001-02       Impact factor: 3.780

9.  Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia.

Authors:  Shakil Ahmad; Asif Ahmed
Journal:  Circ Res       Date:  2004-10-07       Impact factor: 17.367

10.  sFlt-1 gene therapy of follicular thyroid carcinoma.

Authors:  Caisheng Ye; Chong Feng; Shenming Wang; Kent Z Q Wang; Nancy Huang; Xiaoning Liu; Yongjie Lin; Mengfeng Li
Journal:  Endocrinology       Date:  2003-11-06       Impact factor: 4.736

View more
  14 in total

Review 1.  Theoretical models for coronary vascular biomechanics: progress & challenges.

Authors:  Sarah L Waters; Jordi Alastruey; Daniel A Beard; Peter H M Bovendeerd; Peter F Davies; Girija Jayaraman; Oliver E Jensen; Jack Lee; Kim H Parker; Aleksander S Popel; Timothy W Secomb; Maria Siebes; Spencer J Sherwin; Rebecca J Shipley; Nicolas P Smith; Frans N van de Vosse
Journal:  Prog Biophys Mol Biol       Date:  2010-10-30       Impact factor: 3.667

Review 2.  Systems biology of pro-angiogenic therapies targeting the VEGF system.

Authors:  Feilim Mac Gabhann; Amina A Qutub; Brian H Annex; Aleksander S Popel
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010 Nov-Dec

3.  Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Aleksander S Popel
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

4.  VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Christopher D Kontos; Brian H Annex; Aleksander S Popel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

Review 5.  Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Authors:  Prakash Vempati; Aleksander S Popel; Feilim Mac Gabhann
Journal:  Cytokine Growth Factor Rev       Date:  2013-11-27       Impact factor: 7.638

Review 6.  Therapeutic angiogenesis for critical limb ischaemia.

Authors:  Brian H Annex
Journal:  Nat Rev Cardiol       Date:  2013-05-14       Impact factor: 32.419

Review 7.  Stimulus-responsive ultrasound contrast agents for clinical imaging: motivations, demonstrations, and future directions.

Authors:  Andrew P Goodwin; Matthew A Nakatsuka; Robert F Mattrey
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-09-06

8.  Module-based multiscale simulation of angiogenesis in skeletal muscle.

Authors:  Gang Liu; Amina A Qutub; Prakash Vempati; Feilim Mac Gabhann; Aleksander S Popel
Journal:  Theor Biol Med Model       Date:  2011-04-04       Impact factor: 2.432

9.  The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling.

Authors:  Marianne O Stefanini; Florence T H Wu; Feilim Mac Gabhann; Aleksander S Popel
Journal:  PLoS Comput Biol       Date:  2009-12-24       Impact factor: 4.475

10.  Expression of VEGF receptors on endothelial cells in mouse skeletal muscle.

Authors:  Princess I Imoukhuede; Aleksander S Popel
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.